2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Profiling, Treatment Considerations, Drug Development, Drug-Drug Interactions, Supportive Care, Biological Therapies, Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Immunology, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, ALL, Aggressive Lymphoma, Research, Fundamental Science, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pregnant
PAPER

1336 Limitations of the in vitro aPTT assay in assessing the potency of therapeutic FXI inhibitors

Yu-Hsin Chiu, PhD, Xueming Huang2, Alexander W. Koch, PhD3
1 Novartis Biomedical Research, Cambridge, Massachusetts, United States
2 Novartis Biomedical Research, Cambridge, Massachusetts, United States
3 Novartis Biomedical Research, Cambridge, Massachusetts, United States

Introduction: Current oral anticoagulant therapies are effective but carry a significant risk of bleeding, which limits their clinical use. Factor XI (FXI), a key component of the intrinsic coagulation pathway, has emerged as a promising target for anticoagulation because inhibition of activated FXI (FXIa), while largely preserving the extrinsic coagulation pathway, may reduce thrombotic risk with a lower risk of bleeding. The activated partial thromboplastin time (aPTT) assay is commonly used to assess inhibition of enzymes in the intrinsic pathway and can be used to determine the activity of FXIa inhibitors that are highly specific for FXIa. However, published aPTT results vary considerably because assay conditions and experimental setups differ across studies, making direct comparisons between compounds challenging. In this study, we used the exact same assay condition to evaluate three FXI/FXIa inhibitors currently in Phase 3 clinical development that have distinct mechanisms of action: the monoclonal antibody abelacimab and the small-molecule active-site inhibitors milvexian and asundexian.

Methods: Three in vitro coagulation assays were used to assess the activity of these FXI/FXIa inhibitors: the aPTT assay, the one-stage aPTT FXI activity assay, and the thrombin generation assay (TGA). A mechanical coagulometer and a sulfatides/silica surface activator were used for both the aPTT and one-stage assays. In the aPTT assay, FXI/FXIa inhibitors were tested in both normal and FXI deficient plasma to evaluate off-target effects. In the one-stage assay, FXI deficient plasma was mixed with diluted reference plasma treated with FXI/FXIa inhibitors at concentrations observed in clinical studies to evaluate their specific activities. In the TGA assay, a mixture of phospholipids and tissue factor at very low concentration was used as a trigger to generate a small amount of thrombin independent of FXI, which will then be further amplified through thrombin-mediated feedback activation of FXI. A fluorogenic thrombin substrate was used to monitor the generation of thrombin in the TGA.

Results Under identical aPTT assay conditions, abelacimab doubled the clotting time at lower concentration than either small molecule. In addition, abelacimab increased coagulation time in normal human plasma but had no effect in FXI-deficient plasma, whereas milvexian and asundexian prolonged clotting time both in normal and FXI-deficient plasma.

In the one-stage aPTT FXI activity assay at clinically relevant plasma concentrations, abelacimab demonstrated a greater reduction in FXI activity, while milvexian and asundexian were substantially less potent in this assay than would be predicted from the aPTT doubling time in the conventional aPTT assay. These findings suggest that the aPTT assay may overestimate the effect of milvexian and asundexian, potentially because of off-target effects.

In the TGA assay, abelacimab inhibited peak thrombin generation at lower concentration than milvexian and asundexian, consistent with more effective inhibition of thrombin-mediated FXI activation.

Conclusions: Under identical assay conditions, milvexian and asundexian prolonged clotting time in the aPTT assay using FXI deficient plasma while showing an attenuated effect in the one-stage aPTT assay suggesting potential effects on the intrinsic pathway beyond FXI inhibition. These findings indicate that aPTT data should be interpreted with caution when comparing the pharmacodynamic effects of different FXI/FXIa inhibitor classes.

Alexander W. Koch, PhD: Novartis - Current equity holder in publicly-traded company; Novartis - Current Employment